Skip to main content
OpenTrials
Completed

NCT Number: NCT02847065

The Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum RC15_0421

In the US and Europe, bacteremia are ranked the 7th leading cause of death from all causes. E. coli is one of the main microorganism involved, responsible for 30% to 45% of bacteremia. In Europe, bacteremia E. coli, including BLSE phenotype, have a strong impact on public health, causing increased mortality, particularly in the elderly, and an increase in the average hospital stay. However, few studies have specifically concerned with the criteria associated with mortality of elderly patients with BLSE E. coli bacteremia. Finally, improving epidemiological knowledge of the elderly patients with bacteremia due to BLSE E. coli has importance in terms of public health and is a prerequisite to the development of preventive strategies and to improve the short-term prognosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor Bacterial Infections Bacterial Infections and Mycoses Enterobacteriaceae Infections Escherichia coli Infections Gram-Negative Bacterial Infections Infections

Age range

65 year–105 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Nantes

Nantes, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients with positive blood culture E. coli BLSE will be included in the study. Bacteremia E. coli BLSE will be defined as the identification of one or more blood cultures positive for E. coli BLSE in patients with clinical criteria of systemic inflammatory response, at least two of the following 4 criteria:
  • temperature> 38 ° C or < 36 ° C;
  • heart rate> 90 beat / min;
  • respiratory rate > 20 c / min or PaCO2 < 32 mmHg;
  • WBC > 12,000 / microL or < 4000 / microL or 10% immature forms

Exclusion criteria

  • For each patient included, only the first episode of bacteremia will be included in the study

Treatment and study plan

Primary outcomes

  1. Association between advancing age and mortality at 30 days in patients with bacteremia E. coli beta-lactamase phenotype extended spectrum.

    Time frame: 30 days

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Official study title

Study Single-center, Uncontrolled, Retrospective, the Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum

Acronym: MoBaCo

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jul 27, 2016
Registry last updated
Sep 21, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.